Comparison of treatment outcome between living donor liver transplantation and sorafenib for patients with hepatocellular carcinoma beyond the Milan criteria

For patients with advanced hepatocellular carcinoma (HCC), sorafenib is the only systemic treatment recommended by international guidelines. We recently reported that HCC patients with a low MoRAL (model to predict tumor recurrence after LDLT) score (≤ 314.8) have excellent treatment outcomes after...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncotarget
Glavni autori: Cho, Yuri, Lee, Jeong-Hoon, Lee, Dong Hyeon, Cho, Eun Ju, Yu, Su Jong, Yi, Nam-Joon, Lee, Kwang-Woong, Kim, Yoon Jun, Yoon, Jung-Hwan, Suh, Kyung-Suk
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2017
Teme:
Research Paper
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5564586/
https://ncbi.nlm.nih.gov/pubmed/28548930
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.17733
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items